Novo Nordisk (NVO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$50.9B

Revenue (quarter)

$12.0B

Revenue growth (year over year)

−1.11%

Gross profit (trailing twelve months)

$41.0B

Gross margin

80.62%

Net income (trailing twelve months)

$18.0B

Net income (quarter)

$3.2B

Net income growth (year over year)

−23.31%

Net margin

35.28%

Return on equity

59.55%

EPS (trailing twelve months)

$4.05

Book value per share

$7.64

P/E (trailing twelve months)

9.37

Price to book

4.98

Debt to assets

62.81%

Payout ratio

46.44%

Dividend yield

3.49%

Company profile

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

• Is Novo Nordisk (NVO) profitable?

  Yes. Novo Nordisk earned $18.0B in net income over the trailing twelve months, a net margin of 35.28%.

• How much revenue does Novo Nordisk (NVO) make?

  Novo Nordisk generated $50.9B in revenue over the trailing twelve months, down 1.11% year over year.

• What is NVO's P/E ratio?

  Novo Nordisk trades at 9.4 times trailing twelve-month earnings, on an EPS of $4.05.

• How do I buy stock in Novo Nordisk (NVO)?

  NVO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.